Tempus AI（纳斯达克代码：TEM）近日宣布，其研发的AI产品已获得美国食品药品监督管理局（FDA）的批准。这款创新工具旨在利用标准心电图数据，辅助检测肺动脉高压的早期迹象。
据悉，该AI系统通过分析常规心电图信号，能够捕捉到与肺动脉高压相关的细微异常，为临床医生提供更为精准的筛查依据。这一突破性进展，有望显著提升该疾病的诊断效率，尤其是在疾病早期阶段，从而为患者争取宝贵的治疗窗口。
Tempus AI表示，此次监管许可标志着公司在将人工智能技术深度融入心血管疾病诊断领域迈出了坚实一步。公司未来计划继续拓展AI在医疗健康领域的应用边界，推动更多智能化解决方案落地。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.